Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at

Subscribe to WSJ:

Stocks mentioned in the article : SANOFI
Recommend :
React to this article
Latest news on SANOFI
6m ago SANOFI : Information concerning the total number of voting rights and shares, pr..
10h ago Founder of scandal-hit drugmaker Servier dies at 92
1d ago GENZYME : to Resubmit LemtradaTM Application for FDA Review
1d ago SANOFI : Studies from Sanofi Pasteur Add New Findings in the Area of Genital War..
1d ago SANOFI INDIA : : India appoints new country head
1d ago SANOFI : Pitt CVR and Sanofi Pasteur Collaborate to Assess the Effectiveness of ..
1d ago Alnylam Secures Positive Opinion for Orphan Drug Designation in the European ..
2d ago SANOFI : Basketball Hall of Famer Nancy Lieberman Teams Up with New Nasacort® Al..
2d ago PROBI : Sanofi : launches Probi Digestis® in Korea
04/10 SANOFI : Genzyme to Resubmit LemtradaTM Application for FDA Review
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
SANOFI : Income Statement Evolution
More Financials
Dynamic quotes